NCT03556904View on ClinicalTrials.gov

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

July 28, 2023

Study Completion Date

July 28, 2023

Conditions
Prostate Cancer
Interventions
RADIATION

Ablative Radiation Therapy

Radiotherapy will typically be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT (Stereotactic Body Radiation Therapy) with 50 Gy in 5 fractions.

DRUG

Hormone therapy or chemotherapy

Current standard of care dosing with standard agents; hormone therapy or chemotherapy.

Trial Locations (2)

48105

VA Ann Arbor Healthcare System, Ann Arbor

48109

University of Michigan Cancer Center, Ann Arbor

All Listed Sponsors
lead

University of Michigan Rogel Cancer Center

OTHER

NCT03556904 - FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) | Biotech Hunter | Biotech Hunter